登录 | 注册    关注公众号  
微信公众号
搜索
>产品&服务 > 血液瘤CAR靶点

血液瘤CAR靶点

血液瘤CAR靶点
背景介绍
嵌合抗原受体T (CAR-T)细胞疗法是一种治疗肿瘤的新型精准靶向疗法,在血液系统恶性肿瘤治疗中取得了突破性进展,不断为患者带来新希望。研究显示,已有多个细胞表面抗原靶点被发现并被应用于相关的CAR细胞疗法中,如CD19、BMCA等热门靶点,它们在血液系统恶性肿瘤,特别是复发/难治性B细胞恶性肿瘤中取得了巨大的成功,另外,一些针对T细胞恶性肿瘤以及某些顽固型B淋巴细胞肿瘤的相关靶点也表现出良好的临床效果。
为支持CAR细胞疗法在血液系统恶性肿瘤研究进展,ACROBiosystems百普赛斯利用专业的蛋白研发平台、蛋白标记平台、稳定株开发平台和流式细胞分析平台,开发了一系列包括非标记、生物素标记、荧光标记等多种形式的CAR靶点蛋白,可用于免疫、筛选、亲和力检测以及CAR检测质控等研究,全面加速您的CAR细胞疗法药物开发进程。
B cell Leukemia/
Lymphoma
T cell Leukemia/
Lymphoma
Acute Myeloid
Leukemia
Multiple
Myeloma
Hodgkin
Lymphoma

点击查看更多血液瘤靶点蛋白

产品优势

包含CD19、CD20、BCMA、CD22等30+血液瘤靶点

覆盖人、鼠、猴、兔等多种属

高生物活性经ELISA、SPR、FACS等验证

Alexa Fluor 488/555/647、PE、APC、FITC等荧光标记类型

部分产品已完成FDA DMF备案,加速临床/上市申报

验证数据
高纯度——MALS验证
v

The purity of Human CD19 (20-291), Fc Tag, premium grade (Cat. No. CD9-H5251) is more than 90% and the molecular weight of this protein is around 140-160 kDa verified by SEC-MALS.

高生物活性
CD9-H5251

Immobilized FMC63 (Mouse IgG2a) at 1 μg/mL (100 μL/well) can bind Human CD19 (20-291), Fc Tag, premium grade (Cat. No. CD9-H5251) with a linear range of 1-31 ng/mL (QC tested).

申请 Protocol

CD9-H5251

Immobilized Human CD19 (20-291), Fc Tag, premium grade (Cat. No. CD9-H5251) at 5 μg/mL (100 μL/well) can bind FMC63 (Mouse IgG2a) with a linear range of 0.6-5 ng/mL (Routinely tested).

申请 Protocol

高灵敏度
BCA-HF2H3
CD9-HF2H3

Binding activity of FITC-Labeled Human BCMA and CD19 protein from two different vendors were evaluated by the FACS analysis. The result showed that ACRO's Star Staining FITC-Labeled Human BCMA (Cat. No. BCA-HF2H3) and CD19 (Cat. No. CD9-HF2H3) protein have a much higher binding activity than that of the other competitor.

点击咨询

极低非特异背景
极低非特异背景
极低非特异背景

5e5 of PBMCs were stained with AF555-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HA2H7) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and AF555 signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

申请 Protocol

消息提示

请输入您的联系方式,再点击提交!

确定